陕西康惠制药股份有限公司关于变更经营范围并修订《公司章程》的公告

Group 1 - The company plans to change its business scope and amend its Articles of Association to align with strategic planning and regulatory requirements [1][23] - The new business scope includes drug production, wholesale, retail, and various technical services, expanding beyond its previous focus on specific pharmaceutical forms [1][23] - The amendments to the Articles of Association will be submitted for approval at the upcoming extraordinary general meeting of shareholders [1][25] Group 2 - The extraordinary general meeting of shareholders is scheduled for December 26, 2025, and will utilize both on-site and online voting methods [5][6] - The meeting will discuss the approved resolutions from the board meeting, including the change in business scope and the provision of guarantees for a subsidiary's credit application [7][30] - The company has ensured that all necessary disclosures regarding the meeting and resolutions have been made in compliance with regulatory requirements [4][24] Group 3 - The company intends to provide a guarantee of up to 170 million yuan for its wholly-owned subsidiary's credit application, which is expected to enhance the subsidiary's financing efficiency [27][33] - The guarantee will be structured as a joint liability guarantee and is aimed at supporting the subsidiary's business development needs [32][37] - The board of directors has unanimously approved the guarantee proposal, emphasizing that it does not pose risks to the company or its shareholders [39][40]